Teva Specialty & Biosimilar Pipeline
By development stage – as of October 31, 2022
Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of Active Pharmaceutical Ingredients (API), small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strengths in API and generics with our knowledge of innovative drug development. We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments while expanding access to high-quality medicines for our patients across the globe.
Under Regulatory Review
(budesonide and formoterol
(beclomethasone dipropionate HFA)
Biosimilar to Eylea® (aflibercept)
Biosimilar to Prolia® (denosumab)
Biosimilar to Xolair® (omalizumab)
Inflammatory Bowel Disease
Download a PDF version of Teva Specialty and Biosimilar PipelineDownload PDF
Teva specialty & biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
Pipeline is current as of October 31, 2022